Condition
Bacillus Anthracis (Anthrax)
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 4 (1)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01641991Phase 4CompletedPrimary
Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule
NCT00138411Phase 1CompletedPrimary
Monoclonal Antibody for Treatment of Inhalation Anthrax
NCT00133484Phase 2TerminatedPrimary
UMD rPA Regimen Trial in Adults
NCT00170469Phase 2CompletedPrimary
Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed
Showing all 4 trials